Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

• Status: Terminated
• Trial end date: 2019-12-20
• Target enrollment: 0
• Participant gender: All

Summary

Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor.

This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mirati Therapeutics Inc.
• Treatments: Antibodies, Monoclonal; Durvalumab; Histone Deacetylase Inhibitors; Mocetinostat

Criteria

Inclusion Criteria:

• Phase 1-Diagnosis of advanced or metastatic solid tumor; Phase 2-Diagnosis of NSCLC

• Not amenable to treatment with curative intent

• Adequate bone marrow and organ function

Exclusion Criteria:

• Impaired heart function

• Uncontrolled tumor in the brain

• Other active cancer